Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 169

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 169
---
fsky, M.D.  | ​ | ​              | 50,000 | ​ | ​      | — | ​ | ​     | 50,000 |

____________________

| (1) | Represents the cash retainer for serving on our Board and committees of the Board. |

| (2) | No stock awards were granted in 2024. As of December 31, 2024, each of Mr. Herskowitz, Dr. Rosenwald, Mr. Weiss, Mr. Chill and Dr. Zelefsky had 239 shares of unvested restricted stock pursuant to prior awards. |

| (3) | Pursuant to the Advisory Agreement, the Advisor is paid an annual cash fee of $60,000, for the services of Mr. Weiss as Chairman of the Board and Executive Chairman in addition to any and all annual equity incentive grants paid to members of the Board. |

​

| (4) | Mr. Jin was appointed to our Board on October 23, 2024. The amounts shown represent a prorated amounts of fees earned by Mr. Jin under our director compensation program. |

​

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

​

Securities Authorized for Issuance Under Equity Compensation Plans

​

The following table contains information about
our equity compensation plans as of December 31, 2024.

| ​                                                          
 ​                                                          
 ​                                                          
 ​                                                          
 ​                                                          
 ​                                                          
 ​                                                          
 ​                                                          
 ​                                                          
 Plan Category                                              
 ​                                                          | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ |                                    ​ 
 Equity Compensation Plan Information 
                                    ​ 
                                    ​ 
                                    ​ 
                                    ​ 
           Number of securities to be 
              issued upon exercise of 
                 outstanding options, 
                  warrants and rights 
                                  (a) | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ | ​                 
 ​                 
 ​                 
 Weighted-         
 average           
 exercise price of 
 outstanding       
 options, warrants 
 and rights        
 (b)               |        ​ 
        ​ 
        ​ | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ |                     ​ 
                     ​ 
  Number of securities 
   remaining available 
   for future issuance 
          under equity 
    compensation plans 
 (excluding securities 
          reflected in 
           column (a)) 
                   (c)